Search hospitals > Ohio > Columbus
Ohio State University Comprehensive Cancer Center
Claim this profileColumbus, Ohio 43210
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Tumors
Conducts research for Lymphoma
806 reported clinical trials
145 medical researchers
Summary
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Tumors, Lymphoma and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 786 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Uma Borate, MD, Michael V Knopp, MD, PhD, and Alice Mims.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Floor Backes, MDOhio State University Comprehensive Cancer Center1 year of reported clinical research
Expert in Cancer
Studies Ovarian Cancer
21 reported clinical trials
59 drugs studied
Uma Borate, MDOhio State University Comprehensive Cancer Center3 years of reported clinical research
Studies Acute Myeloid Leukemia
Studies Leukemia
16 reported clinical trials
30 drugs studied
Michael V Knopp, MD, PhDThe Ohio State University Wexner Medical Center2 years of reported clinical research
Studies Anterior Cruciate Ligament Injury
Studies Digital PET/CT Imaging
15 reported clinical trials
35 drugs studied
Alice MimsOhio State University Comprehensive Cancer Center3 years of reported clinical research
Expert in Acute Myeloid Leukemia
Expert in Leukemia
16 reported clinical trials
32 drugs studied
Clinical Trials running at Ohio State University Comprehensive Cancer Center
Breast Cancer
Prostate Cancer
Lung Cancer
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Non-Small Cell Lung Cancer
Peritoneal Cancer
Lymphoma
Leukemia
Hormone Therapy
for Breast Cancer
This phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery. Estrogen can cause the growth of estrogen-receptor-positive breast cancer cells. Hormone therapy using fulvestrant may fight estrogen-receptor-positive breast cancer by blocking the use of estrogen by the tumor cells. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fulvestrant together with palbociclib may be an effective treatment for hormone responsive breast cancer.
Recruiting3 awards Phase 29 criteria
Tucatinib Combination
for Breast Cancer
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should continue. Study treatment will continue until disease progression or intolerable side effects. Patients on trial with extracranial disease progression with stable intracranial disease should continue tucatinib into next line of therapy.
Recruiting3 awards Phase 29 criteria
CFI-402257 + Fulvestrant
for Breast Cancer
This trial tests a new drug, CFI-402257, alone and with Fulvestrant in patients with advanced solid tumors and advanced breast cancer. It aims to determine if the drug is safe and effective by studying its effects on the body and cancer cells. Fulvestrant is an established treatment for hormone receptor-positive advanced breast cancer, often used in combination with other therapies to improve outcomes.
Recruiting3 awards Phase 1 & 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ohio State University Comprehensive Cancer Center?
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Tumors, Lymphoma and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 786 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Uma Borate, MD, Michael V Knopp, MD, PhD, and Alice Mims.
Where is Ohio State University Comprehensive Cancer Center located?
The Ohio State University Comprehensive Cancer Center is located at 300 West 10th Avenue, Columbus, OH 43210. For access, take Medical Center Drive to Dodd Drive, turn left, and follow signs to the Wexner Medical Center Garage. Alternatively, use Kinnear Road to King Avenue, turn left onto King, and then left onto Cannon Drive to reach the hospital.
Who should I call to ask about financial aid or insurance network?
**Ohio State University Comprehensive Cancer Center - Contact Information**
- **Financial Counseling Department:** 614-293-0860
- **Financial Assistance:** 614-293-0860
- **Medication Assistance Program:** 614-293-3868
- **Patient Billing Customer Service:** 614-293-2100
- **Medicaid Assistance:** 614-293-0860, option 2
For more details or to apply for financial assistance, please visit the Financial Assistance page on our website.
What insurance does Ohio State University Comprehensive Cancer Center accept?
The Ohio State University Comprehensive Cancer Center (OSUCCC) accepts a wide range of insurance plans, including Medicaid, Medicare, and various exchange health plans. For Medicaid, accepted plans include AmeriHealth Caritas, Buckeye Community Health Plan, CareSource, Humana Healthy Horizons, and Medicaid Ohio Traditional. Medicare recipients are covered under all traditional plans and Medigap coverage, while exchange health plans accepted include CareSource Marketplace, Molina Healthcare of Ohio, and Buckeye AmBetter.
What awards or recognition has Ohio State University Comprehensive Cancer Center received?
The Ohio State University Comprehensive Cancer Center (OSUCCC) in Columbus, Ohio, has been a National Cancer Institute (NCI)-designated comprehensive cancer center since 1976, showcasing its commitment to excellence in research, patient care, education, and community outreach. It has garnered significant funding for research and care, including NCI grants for phase 1, 2, and 3 clinical trials of novel cancer drugs. Additionally, the OSUCCC supports initiatives such as the Pelotonia Institute for Immuno-Oncology and the Center for Cancer Engineering.